# SWAN: Study on the Tolerance and Efficacy of a New Anti-regurgitation Formula (PC-2016-01)

> **NCT02710955** · NA · COMPLETED · sponsor: **United Pharmaceuticals** · enrollment: 100 (actual)

## Conditions studied

- Gastroesophageal Reflux

## Interventions

- **DIETARY_SUPPLEMENT:** Thickened infant formula

## Key facts

- **NCT ID:** NCT02710955
- **Lead sponsor:** United Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-01
- **Primary completion:** 2017-01-21
- **Final completion:** 2017-04-12
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2017-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02710955

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02710955, "SWAN: Study on the Tolerance and Efficacy of a New Anti-regurgitation Formula (PC-2016-01)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02710955. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*